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ABSTRACT 
To explore the anticancer activity of 2, 4, 5, 6-substituted pyrimidines, several ethyl 2-(1-aminocyclobutyl)-5-(benzoy- 
loxy)-6-hydroxy-pyrimidine-4-carboxylate derivatives associated with the different substituted aromatic/aliphatic car- 
boxamides and sulfonamides were synthesized. Different groups and position on phenyl ring attached to the carbox- 
amide and sulfonamide of the pyrimidine led to two set of compounds. Their chemical structures were confirmed by IR, 
1H NMR and LC/MS analysis. Cytotoxicity of all the synthesized compounds were examined on human leukemia cell 
lines (K562 and CEM). The preliminary results showed most of the derivatives exhibited good antitumor activity. Com- 
pound with para chloro substitution among carboxamides and compound with meta dichloro substitution among sul-
phonamides exhibited significant antitumor activity with IC50 value of 14.0 µM and 15.0 µM respectively against K562 
cell line. For comparison among electron donating groups between carboxamides and sulfonamides, compounds with 
para tert-butyl substitution were chosen for further studies. Cell cycle analysis suggests that both tert-butyl substituted 
compounds are able to induce apoptosis. 
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1. Introduction 
Cancer is a terrible disease which is the leading death 
of the human population in some areas of the world. It 
is the second leading cause of death, behind cardio-
vascular disease, in the United States [1]. Cancer may 
affect people at all ages, even fetuses, but the risk for 
most varieties increases with age. Leukemia is a cancer 
of the blood-forming cells. Leukemia is the most com- 
mon childhood cancer, affecting more than 3,500 child- 
ren in the United States every year. At present, there 
are three main methods of cancer treatment: surgery, 
radiation therapy, and chemotherapy. With the devel-
opment of molecular biology, chemotherapy is becom-
ing a more important therapeutic method. Therefore, 
designing new anticancer drugs with high-efficiency 
and broad-spectrum activity is a significant study area 
today. 
Heterocycles are ubiquitous to among pharmacy- 
eutical compounds [2]. Pyrimidine moiety is an impor-
tant class of nitrogen containing heterocycles widely 
used as key building blocks for pharmaceutical agents. 
Pyrimidines have a long and distinguished history ex-
tending from the days of their discovery as important 
constituents of nucleic acids to their current use in the 
chemotherapy of cancer and AIDS. The most important 
pyrimidine derivatives are those upon which biological 
organisms depend. Pyrimidine derivatives possessing 
anticancer activity have been reported in the literature 
[3–9]. Pyrimidine derivatives comprise a diverse and 
interesting group of drugs [2]. The subject has been 
discussed recently [10]. Earlier, a comprehensive re-
view concerning pyrimidines has been published by 
Brown [11]. Pyrimidines in general are extremely im-
portant for their biological activities. In addition to 
above-mentioned activities, pyrimidine derivatives 
possessing analgesic [12], antileishmanial [13], antim-
icrobial [14], antifungal [15], and anti-infective have 
also been reported in the literature. Many other exam-
ples of pyrimidine-based derivatives have been inves-
tigated as potential antitumor agents, including 2-phe- 
nylamino derivatives [16–19], 4-phenylamino deriva-
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tives [20,21], 2.4-bis(phenylamino) derivatives [22], 
4.6-bis(phenylamino) derivatives [23,24], and 4-aryl- 
substituted derivatives [25]. In addition, the pyrimidine 
pharmacophore is found in several fused-ring examples 
of ATP-competitive protein kinase inhibitors, such as 
purines, quinazolines and pyrido-, pyrimido-, pyrazolo-, 
and pyrrolo-pyrimidines [26–28]. In continuation of 
our efforts to get novel and potent heterocyclic anti- 
leukemic agents [29–32], a number of novel pyrimidine 
derivatives were synthesized and evaluated for their 
anticancer activity which we wish to report in this pa-
per. 
2. Methods 
2.1 Chemistry 
Infrared (IR) spectra were recorded using a Jasco 
FTIR-4100 spectrometer in the wave number range of 
4000-400 cm-1. Nuclear magnetic resonance (1H NMR) 
spectra were recorded on a Bruker AM 400 MHz spec-
trometer using DMSO-d6 as solvent and tetramethylsi-
lane as an internal standard. The chemical shifts are ex-
pressed in  and the following abbreviations are used: s 
(singlet), d (doublet), t (triplet), q (quartet) and m (multi-
plet). Mass and purity were recorded on a LC-MSD- 
Trap-XCT. The purity of the compounds was checked by 
thin layer chromatography (TLC). Silica gel column 
chromatography was performed using Merck 7734 silica 
gel (60-120 mesh) and Merck made TLC plates. All the 
reagents and chemicals were from Sigma Aldrich Chemi- 
cals Pvt Ltd. 
2.2.1 Synthesis of Ethyl 2-(1-aminocyclobutyl)-5- 
(benzoyloxy)-6-hydroxypyrimidine- 
4-carboxylate (1) 
For the synthesis of the target key intermediate 1 the re-
action sequences as reported in our previous article were 
followed [33]. The synthesis of compounds 3(a-i) is also 
reported earlier [33]. Treating cyclobutanone with am-
monium chloride and sodium cyanide in methanol gave 
1-isocyanocyclobutanamine. Amine group of 1-isocya- 
nocyclobutanamine was protected by using benzyl chlo- 
roformate in presence of mild base sodium carbonate 
followed by the oxime formation by using hydroxyla- 
mine hydrochloride in presence of base potassium hydro- 
xide and methanol as a solvent to get benzyl 1-amidino- 
cyclobutylcarbamate. This compound on cyclisation with 
diethyl acetylene dicarboxylate in chloroform using trie- 
thylamine as a base for 5 hr yielded benzyl 1-(4-(ethoxy- 
carbonyl)-5, 6-dihy-droxypyrimidin-2-yl) cyclobutylcar-
bamate. Treating the above compound with benzoic an-
hydride in pyridine gave benzyl 1-(4-(ethoxycarbonyl)- 
5-(benzoyloxy)-6-hydroxylpyrimidin-2-yl)cyclobutyl car- 
bamate. Final key intermediate 1 was obtained by depro-
tection of amine group of previous compound by using 
Pd/C in ethyl acetate. 
2.1.2 General Procedure for the Synthesis of Ethyl 
2(1-aminocyclobutyl)-5-(benzoyloxy)-6-hydroxy-
pyrimidine-4-carboxylate Derivatives 2(a-i) 
A solution of ethyl 2-(1-aminocyclobutyl)-5-(benzoy-
loxy)-6-hydroxypyrimidine-4-carboxylate (1) (1.0 eq) in 
dichloromethane was taken and cooled to 0-5 oC in ice 
bath. Triethyl amine (3.0 eq) was added to the cold mix-
ture and stirred for 10 min and respective aryl carbonyl 
chlorides (1.0 eq) were added, the mixture was stirred 
and allowed at room temperature for 5 hr. The progress 
of the reaction was monitored by TLC. Upon completion, 
water was added to reaction mixture and extracted with 
ethyl acetate. The organic layer was washed with 10% 
ammonium chloride solution followed by water wash and 
dried with anhydrous sodium sulphate. The solvent was 
evaporated and the crude product obtained was purified by 
column chromatography over silica gel (60-120 mesh) 
using dichloromethane: methanol (9:1) as eluent. The IR, 
1H NMR and mass spectroscopic data are given in Table 1. 
2.1.3 Synthesis of Ethyl 2-(1-(3,5-dinitrobenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2a) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine- 
4-carboxylate 1 (0.1 g, 0.28 mmol), 3, 5-dinitrobenzoyl 
chloride (0.064 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
2.1.4 Synthesis of Ethyl 2-(1-(3-methoxybenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2b) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine- 
4-carboxylate 1 (0.1 g, 0.28 mmol), 3-methoxy-benzoyl 
chloride (0.048 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
2.1.5 Synthesis of Ethyl 2-(1-(2-fluorobenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2c) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine- 
4-carboxylate 1 (0.1 g, 0.28 mmol), 2-fluorobenzoyl 
chloride (0.044 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
2.1.6 Synthesis of Ethyl 2-(1-(4-tert-butylbenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2d) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine- 
4-carboxylate 1 (0.1 g, 0.28 mmol), 4-tert-butyl-benzoyl 
chloride (0.055 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
Copyright © 2010 SciRes                                                                               JCT 
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Scheme 1. Reagents and conditions: (i) Alkyl/Aryl carbonyl 
chloride, triethylamine, dichloromethane, 0 oC-rt, 6-8 hr; (ii) 
Alkyl/Aryl sulphonyl chloride, triethylamine, dichloro-
methane, 0 oC-rt, 6-8 hr 
 
2.1.7 Synthesis of Ethyl 2-(1-(2,6-difluorobenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2e) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine-
4-carboxylate 1 (0.1 g, 0.28 mmol), 2, 6-difluoro- 
benzoyl chloride (0.049 g, 0.28 mmol) and triethylamine 
(0.085 g, 0.84 mmol). 
2.1.8 Synthesis of Ethyl 2-(1-(3-bromobenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2f) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine-
4-carboxylate 1 (0.1 g, 0.28 mmol), 3-bromobenzoyl 
chloride (0.061 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
2.1.9 Synthesis of Ethyl 2-(1-(4-chlorobenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2g) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine-
4-carboxylate 1 (0.1 g, 0.28 mmol), 4-chlorobenzoyl 
chloride (0.049 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
2.1.10 Synthesis of Ethyl 2-(1-(benzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2h) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimidine-
4-carboxylate 1 (0.1 g, 0.28 mmol), benzoyl chloride 
(0.039 g, 0.28 mmol) and triethylamine (0.085 g, 0.84 
mmol). 
2.1.11 Synthesis of Ethyl 2-(1-(3-nitrobenzamido) 
Cyclobutyl)-5-(benzoyloxy)-6-hydroxy- 
pyrimidine-4-carboxylate (2i) 
The product obtained was white solid from ethyl 2-(1- 
aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimi-dine 
-4-carboxylate 1 (0.1 g, 0.28 mmol), 3-nitrobenzoyl chlo- 
ride (0.052 g, 0.28 mmol) and triethylamine (0.085 g, 
0.84 mmol). 
Table 1. IR, 1H NMR and mass spectroscopic data of com-
pounds 2(a-i) 
Com- 
pound 
No 
IR 
(KBr, 
cm-1)
1H NMR (DMSO-d6, 400 MHz) 
MS 
(M+1) 
m/z 
2a 
3460, 
2930, 
2859, 
2371, 
1681, 
1059
12.85 (s, 1H, -OH), 9.85 (s, 1H, 
-NH), 9.65 (s, 1H, Ar-H), 9.15 (m, 
2H, Ar-H), 7.22 (m, 5H, Ar-H), 
4.24 (q, 2H, -CH2), 2.82 (t, 2H, 
-CH2), 2.45 (t, 2H, -CH2), 1.97 (m, 
2H -CH2), 1.10 (t, 3H, -CH3) 
552.41
2b 
3459, 
2941, 
2848, 
2365, 
1679, 
1065
13.08 (s, 1H, -OH), 9.01 (s, 1H, 
-NH), 8.08 (t, 2H, Ar-H), 7.78 (d, 
1H, Ar-H), 7.63 (m, 1H, Ar-H), 
7.12 (m, 5H, Ar-H), 4.24 (q, 2H, 
-CH2), 3.84 (s, 3H, -OCH3), 2.82 (t, 
2H, -CH2), 2.45 (t, 2H, -CH2), 1.97 
(m, 2H -CH2), 1.10 (t, 3H, -CH3) 
492.17
2c 
3450, 
2959, 
2855, 
2360, 
1665, 
1079, 
790 
12.89 (s, 1H, -OH), 9.80 (s, 1H, 
-NH), 7.78 (t, 1H, Ar-H), 7.38 (t, 
1H, Ar-H), 7.85 (d, 1H, Ar-H), 
7.58 (d, 1H, Ar-H), 7.17 (m, 5H, 
Ar-H), 4.22 (q, 2H, -CH2), 2.75 (t, 
2H, -CH2), 2.42 (t, 2H -CH2), 1.91 
(m, 2H, -CH2), 1.12 (t, 3H, -CH3) 
480.46
2d 
3462, 
2955, 
2848, 
2358, 
1669, 
1045
12.56 (s, 1H, -OH), 10.25 (s, 1H, 
-NH), 8.88 (d, 2H, Ar-H), 7.87 (d, 
2H, Ar-H), 7.44-7.50 (m, 5H, 
Ar-H), 4.22 (q, 2H, -CH2), 2.79 (t, 
2H, -CH2), 2.50 (t, 2H, -CH2), 1.96 
(m, 2H, -CH2), 1.29 (s, 9H, 
-(CH3)3), 1.07 (t, 3H, -CH3) 
518.22
2e 
3434, 
2927, 
2360, 
1666, 
1105, 
794 
12.52 (s, 1H, -OH), 9.85 (s, 1H, 
-NH), 7.91 (dd, 2H, Ar-H), 7.75 
(m, 1H, Ar-H), 7.23 (m, 5H, Ar-H), 
4.25 (q, 2H, -CH2), 2.76 (t, 2H, 
-CH2), 2.53 (t, 2H, -CH2), 1.94 (m, 
2H, -CH2), 1.1 (t, 3H -CH3) 
498.14
2f 
3451, 
2956, 
2854, 
2362, 
1672, 
1046, 
763 
12.95 (s, 1H, -OH), 9.20 (s, 1H, 
-NH), 8.24 (s, 1H, Ar-H), 8.06 (d, 
1H, Ar-H), 7.88 (t, 1H, Ar-H), 7.61 
(m, 5H, Ar-H), 7.48 (d, 1H, Ar-H), 
4.21 (q, 2H, -CH2), 2.78 (t, 2H, 
-CH2), 2.48 (t, 2H -CH2), 1.95 (m, 
2H, -CH2), 1.01 (t, 3H, -CH3) 
541.07
2g 
3458, 
2951, 
2836, 
2355, 
1668, 
723 
12.43 (s, 1H, -OH), 10.21 (s, 1H, 
-NH), 8.91 (d, 2H, Ar-H), 7.93 (d, 
2H, Ar-H), 7.44-7.56 (m, 5H, 
Ar-H), 4.29 (q, 2H, -CH2), 2.73 (t, 
2H, -CH2), 2.48 (t, 2H, -CH2), 1.94 
(m, 2H, -CH2), 1.05 (t, 3H, -CH3) 
496.89
2h 
3450, 
2960, 
2849, 
2356, 
1679
12.79 (s, 1H, -OH), 9.31 (s, 1H, 
-NH), 7.52-7.85 (m, 10H, Ar-H), 
4.25 (q, 2H, -CH2), 2.80 (t, 2H, 
-CH2), 2.49 (t, 2H, -CH2), 2.02 (m, 
2H, -CH2), 1.06 (t, 3H, -CH3) 
462.26
2i 
3462, 
2941, 
2863, 
2358, 
1685, 
1061
12.70 (s, 1H, -OH), 9.25 (s, 1H, 
-NH), 8.22 (s, 1H, Ar-H), 8.12 (d, 
1H, Ar-H), 7.91 (t, 1H, Ar-H), 7.63 
(m, 5H, Ar-H), 7.43 (d, 1H, Ar-H), 
4.24 (q, 2H, -CH2), 2.81 (t, 2H, 
-CH2), 2.50 (t, 2H -CH2), 1.98 (m, 
2H, -CH2), 1.12 (m, 3H, -CH3) 
507.34
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2.2 Biology 
Human cell lines, K562 and CEM were purchased from 
National Center for Cell Science, Pune, India. Cells were 
cultured in RPMI 1640 medium supplemented with 10% 
fetal bovine serum (FBS), 100 U/mL of Penicillin, and 
100 μg of streptomycin/ml and incubated at 37 ºC in a 
humidified atmosphere containing 5% CO2. Leukemia 
(K562 and CEM) cells growing in log phase were treated 
with 10, 50 and 100 μM concentrations of 2, 4, 5, 
6-substituted pyrimidine derivatives 2(a-i) and 3(a-i). 
Since the compounds were dissolved in DMSO, it was 
used as vehicle control. We employed trypan blue dye 
exclusion and MTT assay to assess the cytotoxicity. In 
addition, we have performed cell cycle analysis and 
DNA fragmentation assay to determine the apoptosis. 
Each experiment was repeated a minimum of two times. 
2.2.1 Cytotoxicity Assay 
MTT [3-(4, 5 dimethylthiazol-2-yl-2,5-tetrazolium bro-
mide)] assay was used for the measurement of the cyto-
toxicity of synthesized compounds 2(a-i) and 3(a-i) as 
described previously [19]. In brief, Exponentially grow-
ing K562 or CEM cells (1×104 cells /well) were plated in 
duplicates and incubated with 10, 50 and 100 μM of 2(a-i) 
and 3(a-i). Cells were harvested after 48 and 72 h of 
treatment and incubated with MTT (0.5 mg/ml) at 37°C. 
The water soluble tetrazolium salt, [3-(4, 5-dimethylthi- 
azol-2-yl-2,5-tetrazolium bromide)] is metabolized to the 
water insoluble formazan by intact mitochondrial dehy-
drogenases. The formazan is then solubilized by adding 
detergent. The viability of the cells was estimated on the 
basis of formazan formed, which was detected spectro-
photometrically by optical density at 570 nm. The mean 
absorbance of culture medium was used as the blank and 
was subtracted. IC50 values (concentration of compound 
causing 50% inhibition of cell growth) were estimated 
after 72 h of compound treatment. The absorbance of 
vehicle cells was taken as 100% viability and the values 
of treated cells were calculated as a percentage of control 
and presented as histograms (Figure 1 and Figure 2). 
The antiproliferative effects of these compounds were 
also analyzed by trypan blue exclusion assay against both 
K562 and CEM cells (data not shown). 
2.2.2 Cell Cycle Analysis 
Cellular DNA content was measured by flow cytometry. 
Approximately 7.5×104 cells/ml were cultured and 
treated with 10, 50 and 100 μM concentrations of 2e or 
3f (Figure 3). Cells were harvested after 48 h of treat-
ment, washed, fixed in 70% ethanol and incubated with 
RNase A (Sigma-Aldrich, USA). Propidium iodide (PI, 
50 μg/ml, Sigma-Aldrich, USA) was added half an hour 
before acquiring the flow cytometric reading (FACScan, 
BD Biosciences, USA). A minimum of 10,000 cells were 
acquired per sample and histograms were analyzed by 
using WinMDI 2.8 software. 
3. Results and Discussion 
Pyrimidine ring was derivatized by substituting electron 
withdrawing and electron releasing groups along with 
cyclobutyl carboxamide 2(a-i) and sulfonamide 3(a-i) 
moiety at position 2 of the pyrimidine ring. In addition, 
we also introduced hydroxyl group at position 6, ethyl 
carboxylate at position 4 and phenyl carboxylate at posi-
tion 5 of the pyrimidine. To investigate the cytotoxic 
effects of 2,4,5,6-tetrasubstituted pyrimidines on the 
growth of leukemia cells, a dose response study was 
conducted using trypan blue dye exclusion (data not 
shown) and MTT assay (Figure 1 and Figure 2). Results 
showed that, the cytotoxicity induced by the derivatives  
 
(a)                                                       (b) 
Figure 1. Cytotoxicity as measured by MTT assay. K562 cells treated with 10, 50 and 100 µM of compounds 2(a-i) (a) and 
3(a-i) (b) for 48 and 72 h were harvested and used for the assay. DMSO treated cells were used as vehicle control. Data are 
representative of the mean of two separate experiments done in duplicate 
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(a)                                                     (b) 
Figure 2. Cytotoxicity as measured by MTT assay. CEM cells treated with 10, 50 and 100 µM of compounds 2(a-i) (a) and 
3(a-i) (b) for 48 and 72 h were harvested and used for the assay. DMSO treated cells were used as vehicle control. Data are 
representative of the mean of two separate experiments done in duplicate 
 
(a)                                             (b) 
 
(c)                                        (d) 
Figure 3. Cell cycle analysis of K562 cells treated with 2e or 3f. K562 cells (0.75×105 cells/ml) were incubated at 37 °C with 2e 
or 3f (10, 50 and 100 μM). Following 48 h of incubation, cells were fixed and stained with propidium iodide and subjected to 
FACS analysis. Panel (a) and (b) show histograms comparing the effect of 2e and 3f at specific cell cycle stages. In both the 
Panels (a) and (b), the first histogram represents DMSO treated cells. Panel (c) and (d) show the quantification of cells in 
different stages of cell cycle followed by treatment with 2e and 3f respectively 
 
2(a-i) and 3(a-i) was in a concentration and time depend-
ent manner. Interestingly, the DMSO control corre-
sponding to the highest concentrations of compounds 
tested did not show any significant toxic effect and it was 
taken as 100%. The relative percentage was calculated 
for the treated compounds (Figure 1 and Figure 2). 
These results were further confirmed by trypan blue as-
say (data not shown). Based on these results IC50 values 
Copyright © 2010 SciRes                                                                               JCT 
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were calculated for 72 h and tabulated in Table 2. Com-
pounds 2c, 2d, 2e, 2f, 2g and 2i in carboxamide series 
and compounds 3b, 3c, 3d, 3f and 3i in sulphonamide 
series showed good cytotoxicity. As can be seen from 
Table 2, the electronic property and position of the group 
on the phenyl ring attached to the carboxamide/sulfonamide 
moiety determines the activity of these compounds. 
Among carboxamide derivatives 2(a-i), we found that 
compounds with halogen, nitro and tert-butyl as sub-
stituents on phenyl ring are more cytotoxic compared to 
unsubstituted (2h) and methoxy substituted (2b) deriva-
tives. Compound 2g with chloro at para position on the 
phenyl ring of carboxamide showed good activity with an 
IC50 of 14.0 µM against K562 cells. Among halogen sub-
stitution containing sulfonamide derivatives, compound 
3c with chloro groups at two meta positions showed good 
activity (IC50: 15.0 µM) compared to a chloro at para 
position (3d, IC50: 28 µM) for K562 cells. Similarly, in 
nitro group containing sulfonamide derivatives activity 
varies with the position. Compound 3b with nitro group 
at meta position exhibited more activity (IC50: 26.2 µM) 
relative to compound 3e with an ortho nitro group (IC50: 
36.5 µM) and compound 3a with a para nitro (IC50: 43.1 
µM) against K562 cells. Besides electron withdrawing, 
electron releasing groups also played a role in enhancing 
the activity. 
Compound 3f with tert-butyl group at para position 
exhibited more activity than 3i containing methyl group 
at the same position. This could be due to the presence of 
three electron releasing groups (methyl groups) in 3f and 
only one electron releasing group (methyl group) in 3i. 
More importantly, alkyl group (methyl) directly attached 
to the sulfur atom of the sulfonamide also showed modest 
activity. Interestingly, compound 3g containing only 
phenyl ring lost the activity. This suggest that, electron 
releasing or electron withdrawing group on the phenyl 
ring, or the groups directly attached to the sulfonamide 
moiety contributed to the enhancement of cytotoxicity of 
these compounds. 
Our previous study on the cytotoxic effect of thia-
zolidinone derivatives suggest that, the electron donating 
groups on the C-terminal of the phenyl group at 4th posi-
tion resulted in increasing the activity [32]. Inspired by 
these results, in this series, we have chosen two mole-
cules 2e and 3f containing tert-butyl group at 4th position 
from carboxamide and sulfonamide derivatives respec-
tively for further studies. Firstly, to evaluate the effect of 
2e and 3f on cell cycle progression we have carried out 
flow cytometry analysis. Results showed that both 2e and 
3f did not induce any apoptosis up to 50 µM. At 100 µM 
we have seen a remarkable accumulation of subG1 cells 
followed by the decline of G1, S and G2/M phase cells 
(Figure 3). Therefore, our studies further confirm that 
growth inhibition could be due to apoptosis. 
Table 2. Structure and IC50 values of the synthesised com-
pounds 2(a-i) and 3(a-i) 
IC50 (μM) 
Compound R 
K562 CEM 
2a 
NO2
O2N
 
45.2± 6.8 54.5± 7.2 
2b 
OMe  
>100 >100 
2c 
F  
27.6± 2.6 32.2± 3.8 
2d 
F
F
 
36.1± 3.4 24.3± 2.3 
2e H3C
CH3
H3C
 
40.0± 5.2 34.7± 3.0 
2f 
Br  
50.2± 7.1 22.1± 2.1 
2g 
Cl  
14.0± 2.1 23.0± 2.4 
2h 
 
>100 >100 
2i 
NO2  
35.5± 3.6 48.6± 7.2 
3a 
O2N  
43.1± 6.5 52.3± 7.8 
3b 
O2N
 
26.2± 3.2 45.1± 6.8 
3c 
Cl
Cl  
15.0± 1.6 25.3± 3.8 
3d 
Cl  
28.4± 4.1 30.3± 4.3 
3e 
NO2  
36.5± 4.9 42.1± 6.5 
3f H3C
CH3
H3C  
20.0± 2.3 24.0± 3.0 
3g 
 
>100 >100 
3h H3C  30.2± 4.3 32.3± 4.4 
3i 
H3C  
24.1± 3.1 20.0± 3.4 
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4. Conclusions 
In summary, a series of 2, 4, 5, 6-substituted pyrimidine 
derivatives were synthesized and evaluated for antiprolif-
erative activity against human leukemia cells. From the 
current investigation, structure–activity relationships of 
those compounds suggest both electron donating and elec-
tron withdrawing groups on the phenyl ring attached to the 
sulfonamide group will determine the anticancer activity. 
Compounds with halogen substitution at different positions 
on the phenyl ring of the aryl carboxamide and sulphona-
mide showed good cytotoxicity. From cell cycle analysis, 
it is confirmed that tert-butyl group containing derivatives 
able to could induce apoptosis. Further detailed investiga-
tion on the structure- activity relationship should consider 
the substitution pattern on phenyl ring as a means to lead 
the discovery for more potent cytotoxic compounds. Stud-
ies on the mechanism of action these compounds and 
modification is under progress. 
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